Cargando…
GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
OBJECTIVES: Because of the limitations of randomized controlled trials (RCTs) and observational studies, a prospective, randomized, open-label, blinded endpoint (PROBE) study may be an appropriate alternative, as the design allows the assessment of clinical outcomes in clinical practice settings. Th...
Autores principales: | Cryer, Byron, Li, Chunming, Simon, Lee S, Singh, Gurkirpal, Stillman, Martin J, Berger, Manuela F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590424/ https://www.ncbi.nlm.nih.gov/pubmed/23399552 http://dx.doi.org/10.1038/ajg.2012.467 |
Ejemplares similares
-
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial
por: Cryer, Byron, et al.
Publicado: (2012) -
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
por: Sundar, Raghav, et al.
Publicado: (2022) -
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
por: Laine, Loren, et al.
Publicado: (2012) -
Polarised epithelial monolayers of the gastric mucosa reveal insights into mucosal homeostasis and defence against infection
por: Boccellato, Francesco, et al.
Publicado: (2019) -
Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study
por: Asada, Kiyoshi, et al.
Publicado: (2015)